Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
IDegLira
Description:
IDegLira is a fixed-ratio injectable combination of insulin degludec and liraglutide used to treat type 2 diabetes.
Primary topic:
Diabetes Treatment and Management (85%)
Related topics:
Diabetes Treatment and Management (85%),
Diabetes Management and Research (9%)
OpenAlex ID:
keywords/ideglira
Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes
2014
·
Stephen C L Gough
, Bruce Bode
, et al.
·
The Lancet Diabetes & Endocrinology
·
392
Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)
2014
·
John B. Buse
, Tina Vilsbøll
, et al.
·
Diabetes Care
·
273
Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial
2018
·
Liana K. Billings
, Ankur Doshi
, et al.
·
Diabetes Care
·
211
The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial
2016
·
Sultan Linjawi
, Bruce W. Bode
, et al.
·
Diabetes Therapy
·
143
PDF
Safety and efficacy of insulin degludec/liraglutide ( ID egLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naïve people with Type 2 diabetes: the DUAL IV trial
2016
·
H. W. Rodbard
, B. W. Bode
, et al.
·
Diabetic Medicine
·
119
PDF
Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add‐on to sodium‐glucose co‐transporter‐2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes
2019
·
Athena Philis‐Tsimikas
, Liana K. Billings
, et al.
·
Diabetes Obesity and Metabolism
·
79
PDF
Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial
2017
·
Stewart B. Harris
, Győző Kocsis
, et al.
·
Diabetes Obesity and Metabolism
·
73
PDF
Use and effectiveness of a fixed‐ratio combination of insulin degludec/liraglutide (IDegLira) in a real‐world population with type 2 diabetes: Results from a European, multicentre, retrospective chart review study
2017
·
Hermione Price
, Matthias Blüher
, et al.
·
Diabetes Obesity and Metabolism
·
71
PDF
Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis
2023
·
Irene Caruso
, Ludovico Di Gioia
, et al.
·
EClinicalMedicine
·
65
PDF
Simplifying Complex Insulin Regimens While Preserving Good Glycemic Control in Type 2 Diabetes
2019
·
Zoltán Taybani
, Balázs Bótyik
, et al.
·
Diabetes Therapy
·
63
PDF
Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes
2019
·
Leigh Perreault
, Helena Rodbard
, et al.
·
Advances in Therapy
·
49
PDF
Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?
2018
·
Rodrigo Oliveira Moreira
, Roberta Cobas
, et al.
·
Diabetology & Metabolic Syndrome
·
46
PDF
Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes
2015
·
Stephen CL Gough
, Rajeev Jain
, et al.
·
Expert Review of Endocrinology & Metabolism
·
40
Metabolic Control and Adherence to Therapy in Type 2 Diabetes Mellitus Patients Using IDegLira in a Real-World Setting
2019
·
Cheli Melzer-Cohen
, Gabriel Chodick
, et al.
·
Diabetes Therapy
·
39
PDF
How Does Diabetes Affect Daily Life? A Beyond-A1C Perspective on Unmet Needs
2018
·
Divya Gopisetty
, Brian Levine
, et al.
·
Clinical Diabetes
·
39
PDF
Superior HbA1c control with the fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double‐blind, randomized trial
2019
·
Hirotaka Watada
, Shizuka Kaneko
, et al.
·
Diabetes Obesity and Metabolism
·
37
PDF
Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes
2017
·
Virginia Valentine
, Jennifer Goldman
, et al.
·
Diabetes Therapy
·
37
PDF
Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden
2017
·
Åsa Ericsson
, Adam Lundqvist
·
Applied Health Economics and Health Policy
·
37
PDF
Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting
2016
·
Melanie J. Davies
, Divina Glah
, et al.
·
PharmacoEconomics
·
37
Effect of deprescribing in elderly patients with type 2 diabetes: iDegLira might improve quality of life
2021
·
Stefano Rizza
, Giacomo Piciucchi
, et al.
·
Biomedicine & Pharmacotherapy
·
35
PDF
DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide ( IDegLira ) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin
2021
·
Yu Pei
, Bue R. Agner
, et al.
·
Diabetes Obesity and Metabolism
·
34
PDF
Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes
2018
·
Lawrence Blonde
, John E. Anderson
, et al.
·
Current Medical Research and Opinion
·
33
PDF
Superior efficacy with a fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese patients with type 2 diabetes in a phase 3, open‐label, randomized trial
2019
·
Kohei Kaku
, Eiichi Araki
, et al.
·
Diabetes Obesity and Metabolism
·
32
PDF
An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin
2017
·
Marc Evans
, Liana K. Billings
, et al.
·
Journal of Medical Economics
·
30
PDF
IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy
2015
·
Nick Freemantle
, Muhammad Mamdani
, et al.
·
Diabetes Therapy
·
30
PDF
Show more works
View as search
Works count:
343
Citation count:
3,250
Year
Topic
Type